Wanbangde Pharmaceutical Holding Group Co., Ltd. (WEPON) (SHE: 002082) announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding its plan to conduct a pivotal registration Phase III clinical trial of its self‑developed candidate WP205 (Mecobalamin Injection) for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). The FDA largely accepted the existing non‑clinical pharmacological and toxicological data, agreeing that the completed studies supporting Phase III trials are sufficient to initiate the proposed pivotal registration Phase III trial.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Milestone | Written feedback received on pivotal Phase III trial plan – announced 30 Oct 2026 |
| Product | WP205 (Mecobalamin Injection) – self‑developed by Wanbangde |
| Indication | Amyotrophic lateral sclerosis (ALS / Lou Gehrig’s disease) |
| FDA Position | Largely accepted existing non‑clinical pharmacological and toxicological data; completed studies deemed sufficient to initiate the pivotal registration Phase III trial |
| Next Steps | Company will apply for the pivotal Phase III clinical trial to support regulatory approval in the United States, in alignment with FDA recommendations |
| Trial Design / Timeline | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: WP205, a high‑dose mecobalamin injection developed in‑house by Wanbangde’s innovative drug R&D team to treat ALS.
- Active Substance: Mecobalamin is an active coenzyme form of vitamin B12, involved in neuronal methylation and nerve tissue biology; the high‑dose injectable format is designed to achieve exposures relevant to neurodegenerative disease treatment.
- Quality Standards: WP205 meets FDA quality standards, supported by rigorous preclinical and clinical data generated by the company.
- Regulatory Whitespace: No mecobalamin product is currently approved for marketing in the United States, and Japan is the only country globally where a mecobalamin formulation has gained regulatory approval for the treatment of ALS – leaving WP205 a potential first‑of‑kind approval in the U.S. market.
Disease Landscape – ALS
- Unmet Need: ALS is a progressive neurodegenerative disease leading to loss of voluntary muscle function, with limited approved disease‑modifying therapies and poor prognosis; it affects a substantial patient population in the U.S. with high unmet clinical need.
- Therapeutic Gap: Existing approved ALS treatments offer modest benefit, creating demand for novel mechanisms and formulations such as high‑dose neurotropic agents.
- Precedent in Japan: The approved Japanese mecobalamin ALS experience provides a clinical reference framework that WP205’s U.S. program builds upon with FDA‑quality‑standard manufacturing and a pivotal registration design.
Market Impact & Outlook
- De‑Risked Development Path: FDA agreement that the completed non‑clinical pharmacology and toxicology package is sufficient to proceed materially de‑risks the transition into pivotal development and shortens the regulatory runway.
- First‑in‑Market Potential in the U.S.: With no mecobalamin product approved in the United States, successful completion of the pivotal trial could deliver a novel ALS therapy with no direct same‑molecule U.S. competition.
- Global Expansion Foundation: A U.S. registrational program would extend the mecobalamin ALS franchise beyond Japan, the only current approved market, opening a path for Wanbangde into the world’s largest pharmaceutical market.
- Innovative Drug Transformation: WP205’s advancement underscores Wanbangde’s shift from its traditional pharmaceutical base toward in‑house innovative drug R&D, strengthening its long‑term pipeline identity.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the initiation and conduct of the pivotal Phase III clinical trial, FDA review timelines, and potential regulatory approval of WP205 in the United States. Actual results may differ materially due to risks including clinical trial outcomes, evolving FDA requirements, enrollment timelines, and competitive dynamics in ALS therapy. FDA feedback on trial planning does not constitute approval of the product or guarantee of future marketing authorization.-Fineline Info & Tech
